FDA Advisory Committees Scrutinize Capricor and Replimune Data

By Allison DeAngelis, Adam Feuerstein,and Elaine Chen · STAT News · 2026-07-30

FDA Advisory Committees Scrutinize Capricor and Replimune Data

According to reporting from STAT News, federal regulators and their external advisors are currently evaluating clinical data for two separate high-stakes treatments. The agency is holding public hearings to weigh the efficacy of Capricor Therapeutics’ Duchenne muscular dystrophy

According to reporting from STAT News, federal regulators and their external advisors are currently evaluating clinical data for two separate high-stakes treatments. The agency is holding public hearings to weigh the efficacy of Capricor Therapeutics’ Duchenne muscular dystrophy